
Department of Clinical Pharmacology, Department of Psychiatry and Psychotherapy
Position: Associate Professor
ORCID: 0000-0003-4818-1560
T +43 1 40400 29810
martin.m.bauer@meduniwien.ac.at
Keywords
ATP-Binding Cassette Transporters; Biological Psychiatry; Blood-Brain Barrier; Blood-Retinal Barrier; Clinical Trial, Phase I; Clinical Trial, Phase II; Drug Interactions; Drug Resistance; Epilepsy, Temporal Lobe; Ethics; Organic Anion Transporters; P-Glycoprotein; Pharmacokinetics; Positron-Emission Tomography; Schizophrenia and Disorders with Psychotic Features
Research group(s)
- Section of Clinical Pharmacokinetics / Pharmacogenetics and Imaging
Head: Markus Zeitlinger
Research Area: Our main focus is the study of the drug distribution process by employing techniques to measure target site distribution directly, i.e. PET or microdialysis.
Members:
Research interests
Imaging of transporters influencing the target tissue pharmacokinetics of ABC and OATP substrates is our core expertise. Functional alteration of transporter processes such as up- or down regulation are often observed in various pathophysiological states and may contribute to pharmacoresistancy, drug-drug interactions or vulnerability towards diseases or drug side effects. Thus, the characterization of transporter function and modulation of transporter activity are another focus of our work.
Techniques, methods & infrastructure
Positron-emission tomography (PET) and magnete resonance iamging (MRI) are valuable tools to investigate such processes involved in the absorption, distribution, metabolism, and excretion of a pharmaceutical compound within the human organism. Based on the microdosing concept only sub pharmacological doses of a radiolabelled compound are used to investigate drug distribution and pharmacokinetics in healthy vlunteers and patients. This study setup eases first in human trials and first application of a novel radiotracer for clinical PET imaging.
Selected publications
- Bauer, M. et al., 2020. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology & Therapeutics, 109(3), pp.754–761. Available at: http://dx.doi.org/10.1002/cpt.2052.
- Bauer, M., Tournier, N. & Langer, O., 2019. Imaging P‐Glycoprotein Function at the Blood–Brain Barrier as a Determinant of the Variability in Response to Central Nervous System Drugs. Clinical Pharmacology & Therapeutics. Available at: http://dx.doi.org/10.1002/cpt.1402.
- Bauer, M. et al., 2014. In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 83(15), pp.1326-1331. Available at: http://dx.doi.org/10.1212/WNL.0000000000000858.
- Bauer, M. et al., 2018. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. Journal of Nuclear Medicine, p.jnumed.118.216432. Available at: http://dx.doi.org/10.2967/jnumed.118.216432.
- Bauer, M. et al., 2018. Effect of Rifampicin on the Distribution of [11C]Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 15(10), pp.4589–4598. Available at: http://dx.doi.org/10.1021/acs.molpharmaceut.8b00588.